Search

Your search keyword '"Summers Y."' showing total 34 results
Start Over Author "Summers Y." Search Limiters Peer Reviewed
34 results on '"Summers Y."'

6. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.

Author

Ewertz, M., Herrstedt, J., Karthaus, M., Dubey, S., Davis, R., Fox, G. M., Summers, Y., Jordan, K., von Pawel, J., Jakobsen, A. H., Chan, S., and Naik, J. D.

Subjects
AMISULPRIDE, NAUSEA, DOPAMINE antagonists, VOMITING, CANCER chemotherapy
Abstract

Purpose: Chemotherapy-induced nausea and vomiting (CINV) remain significant clinical problems, especially in the delayed phase (24-120 h after chemotherapy). Amisulpride is a dopamine D2/D3-receptor antagonist previously shown to be an effective intravenous antiemetic. We conducted a randomised, double-blind study to characterise the dose response of oral amisulpride in delayed phase CINV.Methods: Chemotherapy-naïve patients receiving cisplatin ≥ 70 mg/m2 or an anthracycline-cyclophosphamide regimen for breast cancer received, on day 1, 20 mg amisulpride and 8-16 mg ondansetron intravenously followed, once daily on days 2-4, by 10, 20 or 40 mg oral amisulpride or placebo. A control group receiving standard three-drug prophylaxis was enrolled for assay sensitivity purposes. The primary endpoint was complete response (CR), defined as no emesis or rescue medication use, in the delayed phase.Results: Three hundred eighteen subjects were evaluable per protocol. CR rate (24-120 h) was 20% with placebo and 46% with 10 mg amisulpride (p = 0.006 after multiplicity adjustment); in the three-drug control group, it was 59%. Emesis, nausea and 0-120-h CR rate were significantly improved with 10 mg amisulpride compared to placebo. Higher doses of amisulpride were not more effective than 10 mg. In patients with acute phase CR, delayed phase CR rate was 44% for placebo, 75% for 10 mg amisulpride (p = 0.022) and 70% for the 3-drug control. No significant differences were seen between groups in safety parameters.Conclusions: Amisulpride 10 mg orally is safe and superior to placebo at preventing delayed CINV caused by highly emetogenic chemotherapy.Trial Registration: NCT01857232. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

7. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

Author

Fennell, D.A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D.C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., and Ferry, D.

Abstract

The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the cisplatin-based doublet remains the foundation of treatment for the majority of patients with advanced NSCLC. In this respect, changes in practice to various aspects of cisplatin use, such as administration schedules and the choice of methods and frequency of monitoring for toxicities, have contributed to an incremental improvement in patient management and experience. Chemoresistance, however, limits the clinical utility of this drug in patients with advanced NSCLC. Better understanding of the molecular mechanisms of cisplatin resistance, identification of predictive markers and the development of newer, more effective and less toxic platinum agents is required. In addition to maximising potential benefits from advances in molecular biology and associated therapeutics, modification of existing cisplatin-based treatments can still lead to improvements in patient outcomes and experiences. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

10. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.

Author

White, Shane C., Lorigan, Paul, Middleton, Mark R., Anderson, Heather, Valle, Juan, Summers, Yvonne, Burt, Paul A., Arance, Ana, Stout, Ron, Thatcher, Nick, White, S C, Lorigan, P, Middleton, M R, Anderson, H, Valle, J, Summers, Y, Burt, P A, Arance, A, Stout, R, and Thatcher, N

Published
2001
Full Text
View/download PDF

16. Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis.

Author

Yung, B., Elborn, J. S., Campbell, I. A., Summers, Y., Beckles, M., and Woodcock, A. A.

Abstract

The case is described of a potentially life threatening complication relating to the use of a totally implantable venous access device (Port-a-Cath) in a 28 year old patient with cystic fibrosis. The device was inserted in 1990 and used repeatedly for antibiotic therapy without any complications. In 1995, during assessment for double lung transplantation, a 3 cm thrombus was found at the tip of the catheter in the right atrium. Embolisation of the thrombus to the pulmonary arteries occurred after the infusion of recombinant tissue plasminogen activator (rt-PA). Thrombus formation may be associated with totally implantable venous access devices and thromboembolism may occur following the use of thrombolytic agents in the treatment of such thrombosis. [ABSTRACT FROM AUTHOR]

Published
1997

25. Outcomes of octogenarian (≥80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital.

Author

Howell, M., Chiramel, J., Flaum, N., Lewis, A., Summers, Y., Taylor, P.D., Chittalia, A., Sheikh, H., Blackhall, F., and Califano, R.

Subjects
*NON-small-cell lung carcinoma, *HEALTH outcome assessment, *CANCER treatment, *CANCER chemotherapy, *CANCER research, *PATIENTS, CHRISTIE Hospital (Manchester, England)
Published
2016
Full Text
View/download PDF

31. 118 Smoking habits in lung cancer patients and their carers and audit of smoking advice given.

Author

Pankhania, D., Coote, J., Burt, P., Mackereth, P., Finchett, C., Orrett, L., Hodgson, C., Bayman, N., Blackhall, F., Califano, R., Chan, C., Faivre-Finn, C., Harris, M., Lee, L., Pemberton, L., Sheikh, H., Summers, Y., and Taylor, P.

Subjects
*LUNG cancer diagnosis, *LUNG cancer treatment, *SMOKING, *HEALTH, *MEDICAL audit, *CANCER research, *MEDICAL publishing
Published
2016
Full Text
View/download PDF

32. 157 Comparison of outcomes for early small cell lung cancer (SCLC) treated with surgery versus concurrent chemo radiation (CTRT).

Author

Foy, V., Cree, A., Nawaz, M., Faivre-Finn, C., Bayman, N., Sheikh, H., Taylor, P., Blackhall, F., Jones, M.T., Krysiak, P., Shar, R., and Summers, Y.

Subjects
*CANCER treatment, *SMALL cell lung cancer, *CANCER chemotherapy, *CANCER radiotherapy, *HEALTH outcome assessment, *CANCER invasiveness, *COMPARATIVE studies
Published
2016
Full Text
View/download PDF

33. 167: Thoracic radiotherapy in extensive stage small cell lung cancer.

Author

Harris, M.A., Holland, P., Hogley, R., Burt, P.A., Faivre-Finn, C., Bayman, N., Pemberton, L., Lee, L.W., Coote, J.H., Sheikh, H.Y., Chittalia, A.Z., Blackhall, F., Califano, R., Summers, Y., and Taylor, P.

Subjects
*CANCER treatment, *SMALL cell lung cancer, *THORACIC surgery, *RADIOTHERAPY, *CANCER periodicals, *PUBLISHING
Published
2015
Full Text
View/download PDF

34. 113: Do standardised uptake values from PET-CT scans predict EGFR status of lung tumours?

Author

Coote, J.H., Burt, P.A., Rimmer, C.R., Bayman, N., Blackhall, F., Califano, R., Chittalia, A.Z., Faivre-Finn, C., Harris, M.A., Lee, L.W., Pemberton, L., Sheikh, H.Y., Summers, Y., Taylor, P., Wallace, A., and Shing, E.

Subjects
*TREATMENT of lung tumors, *EPIDERMAL growth factor receptors, *POSITRON emission tomography, *CANCER periodicals, *PUBLISHING
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results